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ABSTRACT 
This article focuses on stability indicating RP-HPLC method for simultaneous estimation of 
Frusemide and Amiloride Hydrochloride as API and in tablet dosage form, validation of 
developed method and its application in pharmaceutical companies. Acetonitrile, potassium 
di hydrogen phosphate and phosphoric acid were used.  Chromatographic conditions 
comprised of C18 column (250 × 4.6 mm, 5 µm), mobile phase of phosphate buffer pH 3.0 
and acetonitrile in 50:50 ratio, flow rate at 1 ml/min, ultraviolet detection at 283 nm.  The 
retention time of Frusemide was found to be 3.038 min. and Amiloride Hydrochloride was 
10.002 min. respectively. The linear regression analysis for calibration plots showed 
correlation coefficient, r = 0.99995 at concentration range of 20 to 200 µg/ml for Frusemide 
and r = 0.99925 at concentration range of 10 to 100 µg/ml for Amiloride hydrochloride. The 
stability studied indicated that the drugs are susceptible to wet heat, dry heat, day light, acidic 
and alkaline conditions with maximum degradation in oxidation degradation. Statistical 
analysis proved the developed RP-HPLC method as simple, reproducible and selective for the 
estimation of Frusemide and Amiloride hydrochloride in tablet dosage form and it can be 
employed as stability-indicating method.   
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1. Introduction: 
Frusemide (Fru) is chemically 4-chloro-2-
furfurylamino-5-sulphamoyl benzoic acid. 
It is a potent loop diuretic1. It acts 
primarily by blocking sodium and chloride 
reabsorption in the ascending limb of the 
loop of Henle. Fru helps to conserve 
potassium and minimize the risk of 
alkalosis, in the treatment of oedema 
associated with hepatic cirrhosis and 
congestive heart failure.  
Amiloride hydrochloride (Ami) is 3,5-
diamino-N-(diaminomethylene)-6 
chloropyrazinecarboxamide 
monohydrochloride dehydrate. It is a 
potassium sparing diuretic1. Ami in 
conjunction with thiazide loop diuretics 
such as Fru, reduces overall fluid volume 
in the body and help to control symptoms 
of heart disease, kidney and liver 
disease2,3. Both drugs are official in 
IP4,7, BP5,8 and USP-NF6,9 . 
Several analytical methods have been 
reported for quantitative determination of 
frusemide individually by UV10,11, 
GC12, TLC13, HPLC14,15 and 
Colorimetry16,17 and quantitative 
determination of amiloride hydrochloride 
is carried out by UV18,19, TLC20 and 
HPLC21 methods. Although, many 
methods have been reported in the 
literature for the estimation of Fru and 
Ami individually, but there is no stability 
indicating high-performance liquid 
chromatography (HPLC) method for their 
simultaneous determination in 
pharmaceutical tablet dosage form. 
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The ICH guideline requires that stress 
testing be carried out to elucidate the 
inherent stability characteristics of the 
active substances22.An ideal stability-
indicating method is one that quantifies 
the drug per se and also resolves its 
degradation products. 
The aim of the present work was to 
develop an accurate, specific, reproducible 
and stability indicating method for the 
determination of frusemide and amiloride 
hydrochloride in the presence of its 
degradation products and related 
impurities as per ICH guideline23. 
2. Materials: 
2.1.Reagents: Working reference 
standards of frusemide and amiloride 
hydrochloride were supplied by Elder 
Pharmaceuticals ltd., Mumbai.The 
marketed tablet formulation Amifru (batch 
no. 0605004, Elder Pharmaceuticals) was 
procured from the market. Acetonitrile 
(HPLC grade), potassium di hydrogen 
ortho phosphate (AR grade) and ortho 
phosphoric acid (AR grade) were used for 
mobile phase preparation. 
2.2. Apparatus: A gradient HPLC (Water, 
Germany) with PU–1580 double 
reciprocating pump, UV–1575 UV 
detector, and RP-C18 column (5 µm 
particle size) was used. The RP-HPLC 
system was equipped with winchrom 
software for data processing. Method was 
developed using a HIQ SIL, C18 (250 X 
4.6 mm, 5 µm) column with a flow rate of 
1 ml/min  
3. Methods: 
3.1. Chromatographic conditions: 
Chromatographic separation was achieved 
at 26˚C on a reversed phase column using 
a mobile-phase consisting of acetonitrile 
and 50 mM phosphate buffer (pH of 3.0 ± 
0.05) in the ratio of 50:50 v/v. The flow 
rate was kept at 1 ml/min and detection 
was performed at 283 nm.  The injection 
volume was 10 µl. Standard solution 
containing frusemide and amiloride 
hydrochloride were prepared from stock 
solution by suitable dilution to get a 
concentration of 200 µg/ml and 100 µg/ml 
respectively. 
3.2. Diluent preparation: Mobile phase 
consisting of acetonitrile and phosphate 
buffer (pH of 3.0 ± 0.05) in the ratio of 
50:50 v/v was used as the diluent.  
3.3. Stock solutions preparation of 
frusemide and amiloride hydrochloride: 
Frusemide (20 mg) was accurately 
weighed and transferred to 100 ml 
volumetric flask; 50 ml of diluent was 
added to it and the final volume was made 
upto 100 ml mark using the same solvent. 
The solution was filtered through 0.45 µm 
membrane filter. The solution was 
sonicated for 10 min for degassing. The 
final solution contained 200 µg/ml of 
Frusemide. 
Amiloride hydrochloride (10 mg) was 
accurately weighed and transferred to 100 
ml volumetric flask; 50 ml of mobile 
phase was added to it and final volume 
was made upto 100 ml mark using the 
same solvent. The solution was filtered 
through 0.45 µm membrane filter. The 
solution was sonicated for 10 min for 
degassing. The final solution contained 
100 µg/ml of Amiloride Hydrochloride.  
3.4. Standard preparation of frusemide 
and amiloride hydrochloride: Standard 
solution of frusemide (2, 4, 6, 8, 10, 12, 
14, 16, 18 and 20 ml) was pipetted out in a 
series of ten, 10 ml volumetric flasks 
respectively. The volume in each flask 
was adjusted to 10 ml mark with mobile 
phase and mixed the contents so as to 
obtain a final concentration in the range of 
20 to 200 µg/ml. The solution was filtered 
through 0.45 µm membrane filter. The 
solution was then sonicated for 10 min for 
degassing. This final solution contains 20, 
40, 60, 80, 100, 120, 140, 160, 180 and 
200 µg/ml of Frusemide. The filtered 
solution was injected into the HPLC 
system. The chromatogram is shown in 
figure 1.  
Standard solution of amiloride 
hydrochloride (1, 2, 3, 4, 5, 6, 7, 8, 9 and 
10 ml) was pipetted out in a series of ten, 
10 ml volumetric flasks respectively. The 
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volume in each flask was adjusted to 10 ml 
mark with mobile phase and mixed the 
contents so as to obtain a final 
concentration in the range of 10 to 100 
µg/ml. The solution was filtered through 
0.45 µm membrane filter. The solution 
was then sonicated for 10 min for 
degassing. This final solution contains 10, 
20, 30, 40, 50, 60, 70, 80, 90 and 100 
µg/ml of Frusemide. The filtered solution 
was injected into the HPLC system. The 
chromatogram is shown in figure 2. 
3.5. Synthetic mixture preparation of 
frusemide and amiloride hydrochloride: 
The API mixture of frusemide and 
amiloride hydrochloride was prepared in 
the ratio of 8:1. The decision of this ratio 
of drugs in the API mixture was based 
upon the dosage strength of combination, 
which is available in the market. 
Accurately weighed 80 mg of frusemide 
and 10 mg of amiloride hydrochloride 
were transferred to100 ml volumetric 
flask, dissolved and diluted to 100 ml with 
mobile phase. The solution was filtered 
through 0.45 µm membrane filter. The 
solution was then sonicated for 10 min for 
degassing. The filtered solution was 
injected into the HPLC system. The 
chromatogram is shown in figure 3. 
3.6. Accelerated degradation study of 
synthetic mixture of frusemide and 
amiloride hydrochloride solution 
3.6.1. Wet heat degradation: 100 ml of 
synthetic mixture of frusemide and 
amiloride hydrochloride solution was 
refluxed on a water bath for 1 hour at 
60°C. Then the solution was cooled upto 
room temperature. The solution was 
filtered through 0.45 µm membrane filter 
and was sonicated for 10 min. for 
degassing. The solution was immediately 
injected into the HPLC system and was 
then analyzed. 
3.6.2. Dry heat degradation: The drugs 
were stored in an oven at 105°C for 1 
hour. From this accurately weighed 
frusemide and amiloride hydrochloride in 
the ratio of 8:1 was transferred to 100 ml 
volumetric flask, added 50 ml of mobile 
phase and sonicated to dissolve. Then the 
volume was adjusted to 100 ml with the 
mobile phase. The solution was filtered 
through 0.45 µm membrane filter and was 
sonicated for 10 min. for degassing. The 
solution was immediately injected into the 
HPLC system and was then analyzed. 
3.6.3. Photochemical degradation: 10 ml 
of synthetic mixture of frusemide and 
amiloride hydrochloride solution was 
exposed to direct sunlight for 17 hours. 
The solution was filtered through 0.45 µm 
membrane filter and was sonicated for 10 
min. for degassing. The solution was 
immediately injected into the HPLC 
system and was then analyzed. 
3.6.4. Oxidative degradation: To 10 ml of 
synthetic mixture of frusemide and 
amiloride hydrochloride solution,           10 
ml of 3 % v/v hydrogen peroxide was 
added and the solution was shaken. The 
mixture was allowed to stand for 6 hours. 
The solution was filtered through 0.45 µm 
membrane filter and was sonicated for 10 
min. for degassing. The solution was 
immediately injected into the HPLC 
system and was then analyzed. 
3.6.5. Acidic degradation: To 10 ml of 
stock solution of synthetic mixture of 
frusemide and amiloride hydrochloride 
solution, 10 ml of 0.1 N hydrochloric acid 
was added. This solution was refluxed on 
water bath for 8 hours at 60°C. Then the 
solution was cooled to room temperature. 
The resulting solution was neutralized by 
0.1 N sodium hydroxide solution, to avoid 
any interference of acid. The solution was 
filtered through 0.45 µm membrane filter 
and was sonicated for 10 min. for 
degassing. The solution was immediately 
injected into the HPLC system and was 
then analyzed. 
3.6.6. Alkaline degradation: To 10 ml of 
synthetic mixture of frusemide and 
amiloride hydrochloride solution,          10 
ml of 0.1 N sodium hydroxide was added. 
This solution was refluxed on water bath 
for 8 hours at 60°C. Then the solution was 
cooled to room temperature. The resulting 
solution was neutralized by 0.1 N 
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hydrochloric acid solution, to avoid any 
interference of base. The solution was 
filtered through 0.45 µm membrane filter 
and was sonicated for 10 min. for 
degassing. The solution was immediately 
injected into the HPLC system and was 
then analyzed. 
4.      Results: 
4.1. Method development: The 
chromatographic conditions were 
optimized with a view to develop a 
stability-indicating assay method. It 
included mobile phase of acetonitrile and 
phosphate buffer (pH of 3.0 ± 0.05) in the 
ratio of 50:50 v/v at the detection 
wavelength of 283 nm, acquisition time of 
15 min, injection volume of 10 µl, flow 
rate of 1.0 ml / min and column HIQ SIL, 
250 X 4.6, RP-C18 with 5µm at a 
temperature of 26º C. Except acetonitrile: 
phosphate buffer (50:50), all the other 
mobile phases like pure methanol, 
methanol: phosphate buffer (50:50), 
(90:10) showed too much signal to noise 
ratio (asynchronous and synchronous 
noise), baselines were not proper (there 
was a noisy baseline, drifted baseline and 
cyclic baseline).  At pH = 3.0 ± 0.05, the 
peaks of both the drugs got separated and 
were identified easily which was not in the 
case at pH = 11.0 ± 0.05 (three different 
size peaks were observed in the retention 
time ranging from 2 to 4 min. and they 
were not identified easily) while at pH = 
6.0 ± 0.05, out of three peaks between 2 to 
4 min. one peak got eliminated, second 
peak got very much decreased in size and 
the third peak persist, showed slight 
drifting. Table 1 represents the system 
suitability parameters for the method. 
4.2. Calibration curves: From the 
calibration curve data, the linear 
regression equation and correlation 
coefficient for frusemide was found to be 
y = 8930.7x – 16728, R2 = 0.9999 and 
         r = 0.99995. The method was found 
to be linear in the range of 20 to 200 
µg/ml for frusemide while for amiloride 
hydrochloride it was found to be y 
=10555x + 12633, R2 = 0.9985 and r = 
0.99925, where y is peak area, x is the 
concentration of drug solution and r is the 
correlation coefficient respectively. The 
method was linear in the range of 10 to100 
µg/ml for amiloride Hydrochloride. 
4.3.   Validation of the method 
4.3.1. Accuracy: Accuracy was assessed 
using a minimum of three concentration 
levels in three replicate injections. In a 
preanalysed tablet solution having 80 
µg/ml frusemide and 10 µg/ml amiloride 
hydrochloride, the standard solution of 
frusemide (80, 120 & 160 µg/ml) and 
amiloride hydrochloride (10, 15 & 20 
µg/ml) were added in triplicate. The mean 
% recovery was found to be 99.98% for 
frusemide and 100.22% for amiloride 
hydrochloride. The limit for mean 
recovery is 90-107 %. Thus, the method 
was found to be accurate. Table 2 
represents the accuracy data obtained for 
the method. 
4.3.2. Precision: Precision was measured 
in terms of injection repeatability of 
method developed. Injection repeatability 
was assessed using six determinations at 
100 percent of the test concentration 
80µg/ml and 10µg/ml of frusemide and 
amiloride Hydrochloride respectively. The 
injection repeatability study showed a 
relative standard deviation (RSD) of 0.069 
% for frusemide and 0.400 % for amiloride 
Hydrochloride (≤ 2). Thus, it shows that 
the developed method is sensitive and has 
ability to detect small changes in the 
concentration of drugs in the given sample 
solutions. Therefore, it is concluded that 
the analytical technique showed a good 
repeatability precision. Table 3 represents 
the precision data obtained for the method. 
4.3.3. Robustness: Robustness of the 
method was determined by analyzing 
same sample blend at normal operating 
conditions and also by changing some 
operating analytical conditions such as 
flow rate, pH of the solution. The 
parameters and results of normal operating 
conditions (original) against changed 
conditions are included in Table 4 and 5. 
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These data were subjected to ANOVA test 
to see any significant difference between 
the data sets. No significant (p< 0.02) 
difference in mean % assay was found as 
the calculated value of F is lower than the 
critical value of F. Hence, the robustness 
of the method is established to the extent 
of variations applied to the experimental 
conditions. 
4.3.4. Analysis of the marketed 
formulation: The developed method was 
applied to the analysis of the frusemide 
and amiloride hydrochloride in the 
marketed tablet formulation Amifru (batch 
no. 0605004, Elder Pharmaceuticals). The 
results of analysis are given in Table 6 and 
7. The contents of frusemide and 
amiloride hydrochloride were found in the 
range with RSD less than 2% which 
indicates the suitability of the method for 
routine analysis of frusemide and 
amiloride hydrochloride in pharmaceutical 
dosage forms. 
4.4.Stability indicating property: The % 
drugs recovery, retention time of 
frusemide & amiloride hydrochloride 
(min) with stress conditions and time 
duration are given in Table 8. The stressed 
condition samples are evaluated relative to 
the control sample with respect to % drugs 
recovery, retention time. The high % 
degradation of frusemide & amiloride 
hydrochloride indicates that the drugs are 
susceptible to wet heat, dry heat, day light, 
acidic and alkaline conditions with 
maximum degradation observed in 
oxidation degradation. Dry heat < Wet 
heat < Acid < Alkaline < Day light < 
Oxidation. 
5.Discussion: 
It is evident from the study of RP- HPLC 
method that the newly developed method 
can be used for routine analysis as an 
alternate method for the simultaneous 
estimation of frusemide and amiloride 
Hydrochloride in bulk and tablet dosage 
form. It can also be employed for stability 
studies in the pharmaceutical industry but 
with certain limitations that only HPLC 
grade solvents are to be used for the 
experimental works. All the preparations 
have to be degassed and micro filtered 
before injection into the column. Purging, 
flushing and priming are necessary, both 
before and after the completion of 
experimental works. 
Conclusion: 
The developed HPLC technique is precise, 
accurate and stability indicating. 
Statistical analysis proves that the method 
is reproducible and selective for the 
analysis of Frusemide and Amiloride 
hydrochloride in pharmaceutical tablet 
dosage form. As the method estimates the 
tablet dosage form in presence of their 
degradation products, it can be employed 
as a stability indicating method. 
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Figure 1: Chromatogram of frusemide at 
retention time of 3.040 min. 
 
 
Figure 2: Chromatogram of amiloride 
hydrochloride at retention time of 10.004 min. 
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 Figure 3: Chromatogram of frusemide and 
amiloride hydrochloride at retention time of 
3.038 and 10.002 min. respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1:  System suitability parameters 
 
Parameters Acceptance 
Criteria 
Observation of 
Frusemide 
Observation of 
Amiloride HCl       
Tailing factor 
Theoretical plate 
Asymmetry 
Retention time 
Resolution 
T ≤ 2 
N > 2000 
As ≤ 2 
----- 
Rs > 2 
1.04 
2979 
1.01 
3.040 min 
1.01 
9900 
1.00 
10.004 min 
6.854 
Table 2: Accuracy of frusemide and amiloride hydrochloride in AmifruTM tablet 
Conc. before 
spiking (µg/ml) 
Reference Std. 
added* (µg/ml) 
Conc. after spiking* 
(µg/ml) 
% Recovery 
79.78 
9.66 
79.78 
9.66 
79.78 
9.66 
80 
10 
120 
15 
160 
20 
159.57 
19.65 
199.76 
24.77 
239.64 
29.62 
99.74 
100.10 
99.98 
100.73 
99.91 
99.82 
Mean ± SD# Fru    99.98 ± 0.123 
Mean ± SD# Ami   100.22 ± 0.466 
           * in triplicate 
Table 3: Precision analysis of the method (Injection repeatability analysis) 
Conc. (µg/ml) Peak Area (µV*sec) Mean ± SD % RSD† 
Fru + Ami (80 
+10) µg/ml 
695942 
116494 
694964 
116491 
695955 
116541 
696162 
116380 
696366          
117230 
695874 
117355 
Fru 
    
   695877.20  ± 
482.542 
Ami 
116748.50  ±  
426.52 
Fru 
 
 
0.069 
Ami 
 
0.400 
          † calculated from (SD/Mean*100) 
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Table 4: Robustness of method (Change in the flow rate) 
Inj. Flow 
rate 
ml/min 
Ret. time 
Fru (min) 
Ret. time 
Ami(min) 
P. Area Fru       
( µV*sec) 
P. Area Ami 
(µV*sec) 
A 
B 
C 
mean±SD 
% RSD 
1.0 
0.9 
1.1 
3.040 
4.028 
2.684 
10.004 
11.066 
9.890 
695942 
695564 
697308 
696271.33 ± 
918.00 
0.13 
116494 
115404 
117302 
116400 ±    
952.48 
0.818 
 
Table 5: Robustness of method (Change in the pH) 
Inj. pH  Ret. time 
Fru (min) 
Ret. time 
Ami(min) 
P. Area Fru  ( 
µV*sec)  
P. Area Ami 
(µV*sec) 
A 
B 
C 
mean 
±SD 
% 
RSD¶ 
3.0 
2.7 
3.3 
3.040 
3.125 
3.050 
10.004 
10.022 
10.010 
695942 
695542 
697277 
696253.66 ± 
908.51 
0.130 
116494 
115802 
116300 
116198.7 ±    
356.95 
0.307 
      ¶ calculated from (SD/Mean*100) 
Table 6: Analysis of marketed formulations in AMIFRU TM tablets 
Peak Area (µV*sec) Label Qty. 
(mg/tab) 
Quantity found 
(mg/tab) 
% of Drug 
Fru 
696535 
696374 
696651 
Ami 
117712 
117233 
117732 
Fru 
40 
Ami 
5 
Fru Ami Fru Ami 
39.73 
39.90 
39.91 
39.85 
4.80 
4.80 
4.74 
4.78 
99.33 
99.73 
99.77 
99.61 
95.70 
95.53 
94.84 
95.35 Mean 
Table 7: Statistical analysis of AMIFRU TM 
Parameters Frusemide Amiloride 
hydrochloride 
% Conc. ±SD 
% Coefficient of Variation 
Standard Error Mean (SEM) 
Percentage Range of  Error            
(within 95 % confidence limits) 
99.61 ± 0.243 
0.244 
0.140 
0.274 
95.35 ±           
0.455 
0.477 
0.262 
0.515 
Table 8:  Specific stability study 
Conditions  Time 
Duration 
(hours) 
(%) Drugs recovery of 
Frusemide & Amiloride 
hydrochloride 
 
Retention Time of 
Frusemide & Amiloride 
hydrochloride 
 (min) 
Normal solution 
Wet heat 
Dry heat 
Day light 
Oxidation,H2O2 
Acidic 
Alkaline 
- 
1 
1 
17 
6 
8 
8 
99.86, 99.74 
97.65, 97.50 
98.88, 98.90 
91.82, 89.50 
88.54, 84.20 
96.78, 97.40 
96.65, 96.50 
3.038, 10.002 
3.046, 10.013 
3.041, 10.008 
3.070, 10.038 
3.085, 10.053 
3.051, 10.018 
3.053, 10.016 
 
 
